Arcellx (ACLX)

Executive Summary

Arcellx is a clinical-stage biotechnology company pioneering next-generation cell therapies for cancer and autoimmune diseases. Its proprietary D-Domain technology enables the engineering of CAR-T cells with enhanced activity, safety, and durability. The company's lead candidate, anito-cel (formerly CART-ddBCMA), targets BCMA in relapsed/refractory multiple myeloma and has demonstrated promising efficacy and a favorable safety profile in early trials, potentially differentiating it from approved CAR-T therapies. Arcellx is also advancing an autoimmune pipeline, with anito-cel being studied in myasthenia gravis and other indications, leveraging cell therapy's potential to reset the immune system. Additionally, the company is developing SPRX002, an ARC-T cell therapy for acute myeloid leukemia and myelodysplastic syndromes.

Upcoming Catalysts (preview)

• H2 2026Anito-cel Phase 2 multiple myeloma data update80% success
• 2026Initiation of registrational trial for anito-cel in multiple myeloma90% success
• 2027Phase 1 data update for anito-cel in autoimmune indications60% success